Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project.

Due to the retrospective nature of this study, there may be significant variability and inconsistency in the reporting of toxicity across centers and the use of prophylactic measures (data not collected).

also in 13,097 other papers

However, poor metabolizers (∗28/∗28) compared with extensive and intermediate metabolizers (∗1/∗1 and ∗1/∗28, respectively) showed a trend toward higher incidence of neutropenia (13.3% versus <6%), as well as a higher incidence of grade ≥3 gastrointestinal toxicity (diarrhea and vomiting).

also in 53,322 other papers